Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-03-29 00:00:00 ET · period of report 2023-03-22 · accession 0001140361-23-014592 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-29 | 2023-03-22 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +60.0K | 140.8K | +74% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-22 | A | A | 60,000 | $0.00 | 140,820 | D | — | — | (F1) Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2024, subject to the Reporting Person continuing as a service provider through each such date. (F2) Includes 116,875 RSUs. |